Global Veterinary Parasiticides Market Size By Type (Oral Liquids, Tablets), By Application (Farm Animals, Companion Animals), By Region, And Segment Forecasts, 2023 to 2032

The Global Veterinary Parasiticides Market was valued at USD 9.2 billion in 2023 and is projected to reach USD 15.1 billion by 2031, growing at a CAGR of 6.4% during the forecast period from 2023 to 2031. The rising global demand for animal protein, increased pet ownership, and growing awareness of zoonotic diseases are significant factors propelling the market. Veterinary parasiticides—comprising endoparasiticides, ectoparasiticides, and endectocides—play a critical role in ensuring animal health by preventing and treating infestations that impact both livestock and companion animals.

Drivers:

1. Increasing Companion Animal Adoption and Pet Care Spending:

Growing urbanization and rising disposable income have significantly influenced pet adoption rates, especially in developed countries. Pet owners are increasingly investing in preventive healthcare, including parasiticides, driving market growth.

2. Rise in Livestock Production and Animal-derived Food Demand:

Global meat and dairy consumption continue to rise, prompting farmers to maintain herd health with effective parasitic treatments to ensure productivity and prevent economic losses from parasitic infections.

3. Awareness of Zoonotic Disease Prevention:

Increased public and governmental focus on zoonotic diseases—those transmitted from animals to humans—is encouraging routine veterinary care, including the use of parasiticides in both farm animals and pets.

Restraints:

1. Stringent Regulatory Approval Processes:

Obtaining regulatory approval for new parasiticidal formulations is time-consuming and costly. These hurdles may delay product launches and inhibit innovation, especially for smaller players.

2. Resistance to Parasiticides:

The prolonged and sometimes improper use of parasiticides has led to rising parasite resistance, particularly in livestock, posing challenges for effective treatment and requiring the development of new compounds.

Opportunity:

1. Growth in Emerging Markets:

Rapid expansion of the veterinary healthcare sector in emerging economies such as Brazil, India, and China offers immense growth opportunities. Increasing investments in animal health infrastructure and rising awareness of preventive care are supporting market expansion.

2. Technological Advancements in Drug Delivery:

Innovations such as long-acting injectables, chewable tablets, and spot-on treatments are enhancing ease of administration and efficacy, opening up new product development avenues.

Market by System Type Insights:

Among the product types, endectocides held the largest market share in 2023 due to their dual action against both internal and external parasites. These combination parasiticides are widely preferred for their broad-spectrum activity and ease of use. However, ectoparasiticides are projected to grow at a notable pace, driven by increasing flea and tick infestations among pets, especially in urban environments.

Market by End-use Insights:

In terms of end-use, livestock animals accounted for the dominant market share in 2023. The need to maintain high meat and dairy yields while preventing parasitic disease outbreaks is critical in livestock management. Meanwhile, the companion animal segment is expected to witness the highest growth due to increased spending on pet healthcare, regular deworming programs, and rising awareness about vector-borne diseases.

Market by Regional Insights:

North America led the global veterinary parasiticides market in 2023, driven by high pet ownership, advanced veterinary healthcare infrastructure, and a strong regulatory framework. Asia-Pacific is poised to experience the fastest growth during the forecast period, owing to rapid livestock population growth, increasing urbanization, and expanding access to veterinary services in countries like China, India, and Indonesia.

Competitive Scenario:

Key players in the global veterinary parasiticides market include Zoetis Inc., Elanco Animal Health Incorporated, Boehringer Ingelheim Animal Health, Merck & Co., Inc., Ceva Santé Animale, Virbac, Vetoquinol SA, Bayer AG (now part of Elanco), and Norbrook Laboratories. These companies are investing in product innovation, strategic acquisitions, and global expansion. For instance:

2023: Zoetis launched a new oral chewable targeting flea and tick infestations in dogs, emphasizing ease of use and rapid onset of action.

2024: Boehringer Ingelheim expanded its manufacturing facility in Europe to meet increasing demand for broad-spectrum parasiticides.

2025: Elanco introduced a novel endectocide combining antiparasitic and anti-inflammatory properties, targeting multi-species applications.

Scope of Work – Global Veterinary Parasiticides Market

Key Market Developments:

Zoetis launched new combination parasiticides for broad-spectrum protection in pets.

Elanco completed acquisition of Bayer Animal Health, expanding its parasiticide portfolio.

Merck Animal Health received FDA approval for a new injectable long-acting endoparasiticide.

FAQs:

1. What is the current market size of the Global Veterinary Parasiticides Market?

The market was valued at USD 9.2 billion in 2023.

2. What is the major growth driver of the Global Veterinary Parasiticides Market?

The major growth driver is the increasing demand for pet healthcare and livestock productivity through preventive parasitic treatments.

3. Which is the largest region during the forecast period in the Global Veterinary Parasiticides Market?

North America is expected to dominate the market through 2031 due to advanced animal healthcare infrastructure.

4. Which segment accounted for the largest market share in Global Veterinary Parasiticides Market?

The endectocides segment accounted for the largest share in 2023 due to its dual action against internal and external parasites.

5. Who are the key market players in the Global Veterinary Parasiticides Market?

Key players include Zoetis Inc., Elanco Animal Health, Boehringer Ingelheim, Merck & Co., Ceva, and Virbac.